Title
Category
Credits
Event date
Cost
An Update on the Future of Wilson Disease Management
  • Wilson Disease
  • Genetics
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Due to Wilson disease myriad manifestations, its rarity, and its range of symptoms, differential diagnosis may be challenging, leading to delays in treatment. This Neuroscience Commentary reviews diagnostic acumen and the latest updates in the field.
Recent Advances in Screening for Mild Cognitive Impairment and Alzheimer Disease
  • Alzheimer Disease
  • Cognition
  • Dementia
  • Geriatric Psychiatry
  • Neurology
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Among the most transformative Alzheimer Disease discoveries is the existence of biomarkers which can manifest decades before onset of disease-related dementia.
The Differential Diagnosis and Treatment of Mild Cognitive Impairment and Alzheimer Disease
  • Alzheimer Disease
  • Cognition
  • Dementia
  • Geriatric Psychiatry
  • Neurology
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Navigating the associated differential diagnosis in AD is essential as various causes of cognitive impairment require different treatment strategies.
An Individualized Approach to PAH Therapy Based on Clinical Data, Goal-Directed Therapy, and Risk Stratification 
  • Cardiology
  • Comorbidity
  • Education
  • Integrated Care
  • Medical Conditions
  • Pulmonary Disease
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Pulmonary arterial hypertension requires risk stratification to develop goal-directed treatment plans, including combination therapy targeting multiple pathways.
Tweetorial: Subtle Symptoms of Tardive Dyskinesia Have a Huge Impact on Early Recognition and Intervention
  • Tardive Dyskinesia
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Participation
$0.00
In this Tweetorial learn the causes, signs and symptoms, assessments tools, and treatments for the medication-induced movement disorder tardive dyskinesia.
Improving Clinician Awareness of Rett Syndrome and Optimizing Management of Care Across the Patient Lifespan
  • Rett Syndrome
  • Child and Adolescent Psychiatry
  • Movement Disorders
  • Neurology
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Because of the multiple comorbidities associated with Rett syndrome, clinicians are advised to incorporate clinical guidelines that suggest implementing therapeutics with a multidisciplinary approach and with an eye toward new and emerging therapies. 
Tweetorial: Improving Clinician Awareness of #RettSyndrome and Optimizing Management of Care Across the Patient Lifespan
  • Rett Syndrome
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Participation
$0.00
Because of the multiple comorbidities and symptoms associated with Rett syndrome, clinicians are advised to implement a multidisciplinary approach to disease management with an eye toward new and emerging therapies on the horizon.
Episode 1: Why the Duration Until Onset of Antidepressant Matters
  • Depression
  • Major Depressive Disorder
  • Women’s Mental Health
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Pharmacology for MDD is limited by low efficacy, delayed response, and side effects. Research on the pathophysiology of the disease that includes the glutamatergic system and GABA signaling is ushering in a new era for rapidly acting antidepressants.
Episode 2: Update on Rapid-Onset Therapies for Major Depressive Disorder
  • Depression
  • Major Depressive Disorder
  • Women’s Mental Health
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
The new fast-acting antidepressants esketamine, an NMDA receptor antagonist, and positive allosteric modulators of GABAergic neurotransmission brexanolone and zuranolone have created an important and exciting paradigm shift in the treatment of depression.
Tweetorial: A Rationale for Treating CKD with Combination Therapy
  • Renal Disease
  • Cardiology
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Participation
$0.00
Clinicians have a number of therapeutic agents to choose from when treating T2D at risk of CKD. However, it's important to know how to sequence these therapies in real-world practice.

Pages